Oncology Institute (TOIIW) Amortization of Deferred Charges (2021 - 2026)

Oncology Institute has reported Amortization of Deferred Charges for 6 years, with the latest figure at $1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Amortization of Deferred Charges fell 75.15% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at $4.7 million (down 50.97% YoY), and the FY2025 full-year result was $8.4 million, up 32.91% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $1.2 million, roughly flat from $1.2 million in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $4.9 million in Q1 2025, with the low at $892000.0 in Q3 2022.
• Historically, Amortization of Deferred Charges has averaged $1.6 million across 5 years, with a median of $1.6 million in 2022.
• Annual changes were most pronounced in 2022 — Amortization of Deferred Charges jumped 4855.56% — and 2026, when it tumbled 75.15%.
• Oncology Institute's Amortization of Deferred Charges stood at $1.6 million in 2022, then gained by 1.29% to $1.6 million in 2023, then rose by 1.4% to $1.6 million in 2024, then fell by 24.4% to $1.2 million in 2025, then grew by 0.5% to $1.2 million in 2026.
• The last three Amortization of Deferred Charges figures came in at $1.2 million (Q1 2026), $1.2 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.